Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Eli Lilly’s experimental oral GLP-1 medication, orforglipron, led to an average weight loss of 12.4%, or 27.3 pounds, in a phase 3 trial involving more than 3,000 adults.  Based on the results, the ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

Eli Lilly stock falls after new data on its weight-loss drug Orforglipron, ahead of scheduled second-quarter earnings.

(Reuters) -Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

U.S. equities were mixed at midday in response to more corporate earnings reports and the start of new U.S. tariffs.

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...